Report
Novartis : Last refocusing deal this year? Novartis ready for 2019
>Sandoz: sale of oral generics and dermatology activities in the US - In line with our expectations, Novartis this morning announced the sale of some assets of its Sandoz generics franchise in the US. These concern the dermatology and solid oral generics businesses in the US, which represent sales of around $ 1.2bn per annum ($ 0.6bn in H1 2018), i.e. ~12% of revenues of the Sandoz franchise and around 2.5% of the group’s total sales. The sale of these assets (around...
Underlying
NOVARTIS N 2. LINIE
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Oussema Denguir
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.